Journal of cannabis research最新文献

The purpose of laboratory testing in the cannabis industry is to ensure public safety by preventing products that exceed hazardous limits of contaminants from reaching consumers, and to provide consumers with transparent and accurate label information so that they can make informed decisions when purchasing and using products. However, cannabis testing does not exist in a vacuum of incentives-some incentives exist that are in direct conflict with what is best for consumers. For example, cultivators and distributors will prefer to use the services of laboratories that find the highest THC concentrations or lowest contaminant concentrations, regardless of the accuracy of their testing results. Laboratories will, therefore, be incentivized to serve the cultivators and distributors over the end consumer. The present essay proposes a framework for quality assurance that combats these perverse incentives. The following proposed framework called the Peer-review Blinded Assay Test (P-BAT), is a validation process where each laboratory tests products from competing labs and their own lab, but in a blinded fashion to ensure that the label values of said products and the labs that produced said labels, are unknown. This system of blinded self-review and peer-review is designed to be cost-efficient, transparent, nearly self-funded, can be implemented in any state with two or more laboratories, and most importantly, it is trustless-there is no need to trust the behavior of any one actor or laboratory to serve as a "gold standard". While the primary objective of this process is to focus on laboratory performance, it will also highlight other common problems in the industry such as product adulteration by distributors and poor storge practices. Data from P-BAT should be publicly available so consumers can make informed decisions about their purchases based on the quality data derived from P-BAT. Doing so would further incentivize laboratories to serve and be accountable to the end consumer instead of cultivators and distributors.

Background: Cisplatin is an anti-cancer drug used to treat a plethora of solid tumors. However, it is associated with dose dependent nephrotoxicity limiting its use as anticancer agent.

Objective: The current study aimed to investigate the nephroprotective effect of native Lebanese Cannabis sativa in both in vitro and in vivo mice model of cisplatin-induced nephrotoxicity.

Methods: Podocytes cell viability was assessed using MTS assay with cisplatin (30µM) in presence or absence of Cannabis oil extract (COE) at 0.5, 1 and 2µg/ml for 24h. Acute renal injury was established in adult female C57BL/6 mice with 20mg/kg, i.p. single dose cisplatin. Mice were divided into control group (vehicle), COE group, cisplatin group and cisplatin plus COE (2.5, 5 and 20mg/kg, i.p.). Animal body weight, serum creatinine, blood urea nitrogen (BUN), and proteinuria were measured.

Results: Cell viability assay and western blot analysis revealed that COE prevented apoptosis induced by cisplatin in cultured immortalized rat podocytes. In addition, in vitro scratch assay demonstrated the ability of COE to promote and restore the migratory capacity of podocytes in cisplatin-treated cells. Interestingly, COE treatment improved urinary and serum parameters characterized by a significant decrease in serum creatinine, urea, and proteinuria at various COE doses. Western blot analysis showed that COE inhibited COX-2 protein induction as well as apoptosis marker production (Bax/Bcl2 ratio) in cisplatin-treated mice when compared to mice treated with cisplatin alone.

Conclusion: Collectively, the aforementioned findings indicate that COE could be a promising approach to protect against cisplatin-induced nephrotoxicity.

Background: Differences in cannabinoid metabolism and patient responses can arise even with equivalent doses and formulations. Genetic polymorphisms in genes responsible for cannabinoid metabolism and medications that alter CYP450 pathways responsible for metabolism of cannabinoids may account for some of this variability.

Materials and methods: A retrospective chart review was conducted on a cohort of unselected patients who had previously completed pharmacogenomic testing and reported oral cannabis use, as defined as "oral" or "by mouth" route of administration. The objective was to identify atypical variants and medications in this cohort and formulate a hypothesis on how these variables influence the metabolism of Tetrahydrocannabinol (THC) and Cannabidiol (CBD).

Results: Oral cannabis use was confirmed in 71 patients, with an average age of 68.5 years, and primarily white women. Of the 71 patients, 10 had no atypical variants; 31 had atypical variants in CYP2C9; 37 had atypical variants in CYP2C19; 6 had atypical variants in CYP3A4; and 15 had atypical variants in CYP3A5. Of the 71 patients, 5 were taking medications that could interact with THC, and 8 were taking medications that could interact with CBD.

Conclusion: The results this study reveal the spectrum of hypothesized alterations in THC and CBD metabolism due to atypical genetic variants and medications. The absence of published clinical outcomes in this field renders it challenging to estimate clinical significance of these findings. Until such data become available, clinicians should remain aware of the possibility that atypical variants and medications may impact patients' responses to THC and CBD.

Angiogenesis is an intrinsic physiological process involving the formation of new capillaries from existing ones. Synthetic cannabinoids refer to a class of human-made chemicals that are primarily designed to mimic the effects of delta-9-tetrahydrocannabinol, the primary psychoactive compound in cannabis. Studies investigating the association between synthetic cannabinoids and cellular reactions are limited, and the available scientific evidence is insufficient. Consequently, the primary goal was to examine the effects of the synthetic cannabinoid MDMB-2201 on brain angiogenesis in vitro to provide a comprehensive analysis of MMB-2201's potential therapeutic or adverse effects on vascular development and related health conditions. Human Cerebral Microvascular Endothelial Cells (HBEC-5i) were incubated with MMB-2201, and their metabolic activity, migration rate, and tubular structure formation were examined. Expression levels of several angiogenesis-related proteins such as vascular endothelial growth factor (VEGF), Angiopoietin-1 (ANG-1), and Angiopoietin-2 (ANG-2) were assessed using western blot, ELISA, and real-time PCR. Furthermore, the phosphorylation of glycogen synthase kinase 3 beta (GSK-3β) at Ser9 induced by MMB-2201 was evaluated. HBEC-5i cells showed a significant increase in metabolic rate, enhanced migration, and sprouting of brain endothelial cells. Moreover, there was a noticeable increase in the mRNA and protein levels of VEGF, ANG-1, and ANG-2, as well as in the phosphorylation rate of GSK-3β at Ser9. This study paves the way for a novel pharmacological approach to addressing various angiogenesis-related diseases by targeting cannabinoid receptor type-1. Further exploration using different antagonists or agonists of cannabinoid receptors, depending on the specific characteristics of the disorders, may be necessary.

Modified atmosphere packaging (MAP) alters the gaseous composition of air surrounding packaged goods to prevent deleterious oxidation associated reactions. MAP has been adopted for the storage of cannabis, though a recent study revealed little difference in terpene content under MAP conditions. Questions regarding its efficacy for preservation of high value compounds like terpenes and cannabinoids lost during postharvest storage remain. The goal of this research is to determine weather N₂ MAP preserves high value compounds of cannabis during its postharvest storage. This experiment followed a completed randomized block design. There were two factors of interest. The first was storage atmosphere (atmospheric or N₂ MAP). The second was storage duration (18, 46, or 74 days). The experiment was then blocked by cannabis chemovar using 5 different chemovars. The concentration of 17 cannabinoids was evaluated through UPLC-UV and 61 volatile terpene compounds through GC-MS. Concentrations were compared over time and between storage treatments. There were no significant differences in total cannabinoids and volatile terpene compounds over time or between storage treatments. Individual cannabinoids Δ⁹-THC, CBG, CBNA, CBC, THCV, and THCVA all increased during storage time while THCA decreased. CBG and THCV only increased under MAP storage. Individual aromatics limonene, β-pinene, α-pinene, camphene, and terpinolene all only decreased during storage under N₂ MAP. Only caryophyllene oxide and α-humulene increased under N₂ MAP storage. β-Myrcene decreased under atmospheric storage, but not under N₂ MAP. While N₂ MAP had no effect on the preservation of total cannabinoids and aromatics during storage, it did influence several individual compounds. CBG, THCV, and α-humulene all increased under N₂ MAP. N2 MAP also maintained the concentration β-myrcene over time, though the preservation of β-myrcene was offset by a decrease limonene. Overall, N₂ MAP was not needed for preservation of most high value compounds but did have an effect of some compounds with reputed therapeutic benefits.

Purpose: We conducted this study to assess cannabis use rates in the state of Kentucky relative to socioeconomic, demographic, and geographic factors, as well as reasons for use and modes of use, before the legal medical marijuana market commences in 2025.

Methods: We pooled Kentucky Behavioral Risk Factor Surveillance System (BRFSS) data for 2020-2021 and used weighted responses for all analyses. We estimated current cannabis use (at least once in the past 30 days), and heavy use (at least 20 of the past 30 days) prevalence rates for Appalachian, Delta, and Central geographic regions of Kentucky. We tabulated descriptive statistics and used multivariable logistic regression to identify characteristics of individuals who used cannabis.

Results: The prevalence of cannabis use was lower in Kentucky (10%) than nationally (about 13%). Of those who used cannabis, 42% used it daily or near daily. Those who were male, ages 18-34, never married, black, less than HS education, lower household income, and lived in the Central region were more likely to use cannabis. Among those who used cannabis, mode of use varied somewhat among age groups, education levels, income groups, and marital status, but smoking was most common-78% overall. About 33% reported using cannabis for recreation alone, 24% for medical reasons alone, and 43% for both reasons.

Conclusion: Despite the illegal status of cannabis in Kentucky, its use is common across population sub-groups. A large proportion of Kentuckians using cannabis do so daily or near daily, and most for a medical purpose. Smoking, however, remains the most common mode of use.

Cannabis flower scent is one of the key characteristics of the cannabis plant. The diverse scents impact user experiences and offer medicinal benefits. These scents originate from volatile compounds, particularly terpenes and terpenoids. This study characterized the volatile profile of 19 different dried cannabis flowers using gas chromatography-mass spectrometry coupled with headspace-solid phase microextraction (HS-SPME-GC-MS). A total of 75 compounds were identified, including alcohols, aldehydes, benzenes, esters, ketone, monoterpenes, monoterpenoids, sesquiterpenes, and sesquiterpenoids. Cluster analysis was able to group the 19 cannabis cultivars into five clusters based on volatile chemotypes using chemometric techniques of hierarchical cluster analysis (HCA) and principal component analysis (PCA). Potential discriminant markers of each cultivar were then analyzed using a supervised partial least squares discriminant analysis (PLS-DA) verified through Variable Importance in Projection values (VIP), identifying twenty discriminant markers. In addition, the correlations among 75 volatile compounds were also obtained. The findings of this study provide a valuable database of single cannabis cultivars, useful for identifying individual strains and verifying their quality. Clustering the cultivars by volatile chemotype can be used for the classification of cannabis in the market. The results of this study are expected to be a starting point for further cannabis breeding programs to expand knowledge of this plant. Furthermore, the proposed method is applicable to other aroma plants in the future.

Background: Anxiety disorders (ADs) are a complex group of mental disorders and majorly contribute to the global health-related burden. Symptoms and clinical management differ widely depending on the specific diagnosis. There is a need for new, more effective pharmacological treatments for these patients as many patients do not respond to treatment and treatment is not available for several types of AD. The increased interest in the potential effects of cannabidiol (CBD) on symptoms of AD has led to several preclinical and clinical studies that suggest that CBD may be effective in some patients with AD. However, it remains unclear whether and how CBD can be used in the clinical management of ADs due to a lack of sufficiently robust clinical evidence.

Comparative evaluation: This narrative review provides a critical analysis of the current state of the art for ADs and summarizes six recently completed and 22 currently ongoing clinical trials investigating the effects of CBD on ADs or anxiety. The aim was to examine whether the ongoing trials are likely to provide the necessary solid evidence, or whether new studies with more robust design parameters can help to overcome the prevailing lack of solid clinical data for this CBD indication. Most of the trials reviewed are considered exploratory and do not focus on specific types of clinical anxiety or ADs as the primary condition studied. Participant numbers, CBD dose, treatment duration, and CBD formulation vary widely among the studies, and all but two are single-center studies.

Conclusion: For an effective clinical management of ADs using CBD, there is a need for sufficiently powered and appropriately designed clinical trials (RCT, multicenter, defined doses and exposure monitoring, robust primary outcomes) investigating the effect of CBD in specific ADs, such as social anxiety disorder and panic disorder, or in post-traumatic stress disorder.

Background: Studies investigating the association between cannabis use and physical activity have had mixed results. This study provided a population-based assessment while determining how the relationship is affected by variables such as cannabis legalization status and chronic medical conditions.

Methods: Behavior Risk Factor Surveillance System (BRFSS) data were used to evaluate the association between cannabis use and physical activity among adults ages 18 years and older in several states and territories of the U.S. during 2016-2022. Adjusted odds ratios (ORs) measuring the relationship between physical activity in the past 30 days (yes vs. no) and cannabis use in the past 30 days (yes vs. no) based on legalization and health status were estimated using logistic regression.

Results: Physical activity increased from 73.16% in 2016 to 75.72% in 2022 (3.5% increase) and current cannabis use increased from 7.48% in 2016 to 14.71% in 2022 (96.7% increase). Current cannabis use was 6.5% higher in areas of legalized recreational cannabis (vs. not legal) and 0.7% higher in areas of legalized medical cannabis (vs. not legal). For the combined years, the OR measuring the association between cannabis use and physical activity was 1.24 (95% CI 1.10-1.41), after adjusting for age, sex, race/ethnicity, marital status, employment status, education, smoking status, weight classification, legal status, and chronic medical condition. The adjusted OR was 1.47 (95% CI 1.34-1.62) in areas with legalized recreational and medical cannabis (vs. illegal) and 1.05 (95% CI 0.98-1.12) in areas with legalized medical cannabis only (vs. illegal). Having a medical condition was significantly associated with lower prevalence of physical activity in the adjusted models (overall adjusted OR = 0.79, 95% CI 0.73-0.85). However, this significantly lower odds ratio was insignificant for current cannabis users.

Conclusions: Public policy and personal health behaviors may improve with the findings that legal medical cannabis promotes greater physical activity in those experiencing chronic medical conditions and legal recreational cannabis promotes (even more so) greater physical activity in those not experiencing chronic medical conditions.